Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2019 1
2020 1
2022 3
2023 4
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

9 results

Results by year

Filters applied: . Clear all
Page 1
ARID1A-deficient cells require HDAC6 for progression of endometrial carcinoma.
Megino-Luque C, Sisó P, Mota-Martorell N, Navaridas R, de la Rosa I, Urdanibia I, Albertí-Valls M, Santacana M, Pinyol M, Bonifaci N, Macià A, Llobet-Navas D, Gatius S, Matias-Guiu X, Eritja N. Megino-Luque C, et al. Mol Oncol. 2022 Jun;16(11):2235-2259. doi: 10.1002/1878-0261.13193. Epub 2022 Mar 2. Mol Oncol. 2022. PMID: 35167193 Free PMC article.
RBFOX2 deregulation promotes pancreatic cancer progression and metastasis through alternative splicing.
Maurin M, Ranjouri M, Megino-Luque C, Newberg JY, Du D, Martin K, Miner RE 3rd, Prater MS, Wee DKB, Centeno B, Pruett-Miller SM, Stewart P, Fleming JB, Yu X, Bravo-Cordero JJ, Guccione E, Black MA, Mann KM. Maurin M, et al. Among authors: megino luque c. Nat Commun. 2023 Dec 19;14(1):8444. doi: 10.1038/s41467-023-44126-w. Nat Commun. 2023. PMID: 38114498 Free PMC article.
M-CSF as a therapeutic target in BRAFV600E melanoma resistant to BRAF inhibitors.
Barceló C, Sisó P, de la Rosa I, Megino-Luque C, Navaridas R, Maiques O, Urdanibia I, Eritja N, Soria X, Potrony M, Calbet-Llopart N, Puig S, Matías-Guiu X, Martí RM, Macià A. Barceló C, et al. Among authors: megino luque c. Br J Cancer. 2022 Oct;127(6):1142-1152. doi: 10.1038/s41416-022-01886-4. Epub 2022 Jun 20. Br J Cancer. 2022. PMID: 35725813 Free PMC article.
Transient and DNA-free in vivo CRISPR/Cas9 genome editing for flexible modeling of endometrial carcinogenesis.
Navaridas R, Vidal-Sabanés M, Ruiz-Mitjana A, Perramon-Güell A, Megino-Luque C, Llobet-Navas D, Matias-Guiu X, Egea J, Encinas M, Bardia L, Colombelli J, Dolcet X. Navaridas R, et al. Among authors: megino luque c. Cancer Commun (Lond). 2023 May;43(5):620-624. doi: 10.1002/cac2.12409. Epub 2023 Feb 10. Cancer Commun (Lond). 2023. PMID: 36762520 Free PMC article. No abstract available.
Therapeutic potential of the new TRIB3-mediated cell autophagy anticancer drug ABTL0812 in endometrial cancer.
Felip I, Moiola CP, Megino-Luque C, Lopez-Gil C, Cabrera S, Solé-Sánchez S, Muñoz-Guardiola P, Megias-Roda E, Pérez-Montoyo H, Alfon J, Yeste-Velasco M, Santacana M, Dolcet X, Reques A, Oaknin A, Rodríguez-Freixinos V, Lizcano JM, Domènech C, Gil-Moreno A, Matias-Guiu X, Colas E, Eritja N. Felip I, et al. Among authors: megino luque c. Gynecol Oncol. 2019 May;153(2):425-435. doi: 10.1016/j.ygyno.2019.03.002. Epub 2019 Mar 7. Gynecol Oncol. 2019. PMID: 30853360
Metabolomic Analysis Points to Bioactive Lipid Species and Acireductone Dioxygenase 1 (ADI1) as Potential Therapeutic Targets in Poor Prognosis Endometrial Cancer.
Gatius S, Jove M, Megino-Luque C, Albertí-Valls M, Yeramian A, Bonifaci N, Piñol M, Santacana M, Pradas I, Llobet-Navas D, Pamplona R, Matías-Guiu X, Eritja N. Gatius S, et al. Among authors: megino luque c. Cancers (Basel). 2022 Jun 8;14(12):2842. doi: 10.3390/cancers14122842. Cancers (Basel). 2022. PMID: 35740505 Free PMC article.